AAM Blasts Build Back Better But Bernstein Offers Balance

Discounted Drugs Could Disincentivize US Biosimilar Competition, Says AAM

09 Dec 2021

Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.

Joe Biden stands in front of a Build Back Better poster — Build Back Better's proposed price controls could have a negative affect on the biosimilars industry • Source: Alamy

The US Association for Accessible Medicines has continued to criticize the Biden administration’s proposed Build Back Better Act due to the negative affect it could have on the biosimilars industry. The organization maintains that, as it currently stands, allowing free biosimilar competition will achieve more savings for patients than Build Back Better’s price negotiation model.

Under the proposal, the Department of Health and Human Services would have the authority to negotiate drug prices with manufacturers,...